Oxford, United Kingdom
MiroBio Ltd, a biotechnology innovator founded in 2019, is at the forefront of developing transformational immunotherapies aimed at restoring immune balance to treat autoimmune diseases. Headquartered in the United Kingdom, the company operates under the mission of "Restoring balance to the immune system to treat disease."
MiroBio is pioneering a new class of therapies based on precise activation of inhibitory pathways—an emerging domain in immunology. Their pipeline, comprising agonistic antibodies, is the product of over a decade of foundational research, offering the potential for durable remission in chronic conditions characterized by immune imbalance.
In its strategic growth, MiroBio secured a significant £80.00M Series B investment on 29 June 2022 from a consortium of top-tier investors including Advent Life Sciences, OrbiMed, Monograph Capital, Oxford Science Enterprises, Samsara BioCapital, SR One, and Medicxi. This robust financial backing underscores investor confidence in MiroBio's innovative approach and potential market impact.
BreezeBio